Diagnostic value of total prostate specifc antigen (TPSA) in women with breast cancer in the molecular subtyping era.
The purpose of this study was to identify the diagnostic value of serum levels of total prostate-specific antigen (TPSA) in female patients under different clinical or pathological conditions of the breast. Blood samples from 73 women with breast cancer were prospectively analyzed for serum levels of TPSA, carcinoembryonie antigen (CEA), and carbohydrate antigen 15.3 (CA15.3) before surgery, and compared with the levels of a control group of 78 women with benign breast disease and 22 women with breast cancer metastasis. The serum levels of TPSA, CEA, and CA15.3 were significantly higher in women with breast cancer than in women with benign breast diseases (0.018±0.027 vs 0.007±0.008, p=0.001; 2.338±1.681 vs 1.699±1.164, p=0.008; 13.929±7.679 vs 10.415±5.295, p=0.001, respectively). Serum CEA and CA15.3 levels were significantly higher in patients with cancer metastasis compared with patients with benign breast disease (3.405±2.131 vs 1.699±1.164, p=0.001; 20.255±21.120 vs 10.415±5.295, p=0.042, respectively). Moreover, TPSA levels were significantly associated with menstruation status in breast cancer patients (p=0.030), whereas no significant association was found between TPSA levels and four molecular subtypes (luminal A , luminal B , triple-negative and HER2 ). TPSA serum levels were positively associated with both CEA (p=0.040, R=0.045) and CA15.3 (p=0.032, R=0.049) levels when diagnosing breast cancer. This study indicated the clinical significance for TPSA levels in breast cancer diagnosis. TPSA may act as a useful serologic indicator of future cancer recurrence.